UK markets closed

AbbVie Inc. (0QCV.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
146.95-0.42 (-0.28%)
At close: 07:14PM BST

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • t
    the bman
    I got in at 160 then Buffet sold now in the hole collecting dividend hope he is not right
  • D
    Markets up 500+ points an ABBV is in the red?
  • j
    "To make a long story short, no, it's not time to buy AbbVie stock. Shares are consolidating and will likely struggle to gain footing above their 50-day line. Savvy investors look for stocks that have broken out and are within the 5% chase zone."
  • S
    Was looking good over $143 there for a while. People are pumping the other sectors. Only a matter of time before this is back over $150
  • T
    ABBV seems to head the opposite way of the market. Cost basis 77.24 and my effective yield is 7.3 so I’m hardly complaining.
  • S
    I actually added shares today. I think they are doing quite well in this environment
  • D
    Still pays out $1.41 dividend and makes lots of money.
  • S
    Revenue was up from same time last year. 14.58 bil vs 13.96 bil. Impressive given the economy
  • n
    hope 147 soon..
  • A
    Huge overreaction. Big buying opportunity.
  • D
    Even in depression people need medicine. Rally in tech is only temporary, defense in the long haul…..
  • J
    Such a solid company. Who is selling here in large quantities?
  • R
    Historically, the stock market has generally risen after 2 consecutive quarters of negative GDP
  • D
    Dire Wolf
    This is bound to bounce back - way oversold for whatever reason
  • K
    That was a great opportunity to add at a discount caused by miscalculation about the significance of settling what could've potentially become a catastrophic jury awards of unimaginable dimensions punitive damages for a finite $2 billion and close the case.
    $2 billion is a large sum but quite manageable in context.
    The better way to look at it, is to think of it as ABBV having had to pay an additional $2 billion to buy Allergan.
    The Allergan deal is the gift that keeps on giving for me as i used the crash caused by the announcement to start a large position between the mid to high 60's and now to add more at $139.50.
  • S
    Not bad report. But not a blockbuster by any means. Looks like they had some acquisition costs and litigation fees related to opioid settlement
  • B
    So many "experts" commenting on this board. ABBV is a great long-term holding. DRIP the divvys and you will have substantial gains in this stock over time. Pipeline strong, balance sheet rock solid. Stocks go up and down, ignore the noise and add to any short term drop. Btw, IMO the reason for the drop was more due to the 2+ billion set aside for potential litigation from the Allergan opioid news. Kind of blindsided investors.
  • P
    Government now beginning to focus on drug pricing. Will be front and center the rest of the year. Not good for Pharma, ABBV in particular.
  • D
    146 and 147 was a gift this morning, will probably be back over 150 before end of day.
  • E
    ABBV's share price dropped today by more than 4%, mostly b/c it missed Wall Street's revenue estimate by a bit. No worries, though. ABBV's fundamental strenghts will push past this brief bit of negativity.